Loading company
Vanda Pharmaceuticals Inc.
VNDA · Nasdaq · ·
Next earnings: November 4, 2026
$5.02-2.7%Sep 29 close
- 1M
- -5.1%
- 6M
- -24.5%
- 1Y
- +0.6%
- 5Y
- -71.4%
VNDA · Nasdaq · ·
Next earnings: November 4, 2026
$5.02-2.7%Sep 29 close
Vanda Pharmaceuticals Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $50.5M | $52.6M | -3.92% |
| Profit | -$62.5M | -$27.2M | -129.77% |
| Profit per share | -$1.04 | -$0.46 | -126.09% |
| Free Cash Flow | -$31.3M | -$15.6M | -101.02% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to patients. With BYSANTI approved and on track for launch in the second half of 2026, a December 2026 PDUFA date for Quimilza and multiple late-stage clinical trial results expected before year-end, we believe Vanda is well positioned for meaningful commercial expansion and pipeline value creation,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Vanda Pharmaceuticals Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Vanda Pharmaceuticals Inc. has no earnings call transcript available.